Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

Clinical trial NCT03751709 · COMPLETED

Trial details

NCT number: NCT03751709
Sponsor: Cedars-Sinai Medical Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

B-Cell Acute Lymphoblastic Leukaemia ALL, Adult B-ALL

Start date: 2020-02-14
Primary completion: 2023-03-27
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.